Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREST-KT: Empagliflozin in Kidney Transplant Recipients
NCT04906213Phase 2Terminated
- Sponsor
- Duke University
- Start
- Jul 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin, sponsored by Duke University. Started Jul 2022; status: terminated.
02
Drugs
empagliflozin
Beyond the preview
Go deeper on NCT04906213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906213.